ClinicalTrials.gg
CompletedNCT06855368ADvanceUpdated Nov 4, 2026

Biomarkers for Monitoring Dementia Progression

An observational study in Alzheimer Disease, sponsored by IRCCS San Raffaele Roma. Completed at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by IRCCS San Raffaele Roma · Observational

How we know

Updated Nov 4, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 206 studies in Alzheimer Disease with a site in Italy — 53 open to participants now, 72 under way, 19 of them phase 3. Alzheimer Disease · Italy.

Enrollment
16th of 36
300 · median 273
Started
2023
with 15 others
Observational
36 of 206
18 open now
Registered
166th of 206
by date

Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 16th largest by enrollment of the 36 observational ones that give a count, is one of 16 that started in 2023, is one of 36 observational ones, and was the 166th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

53 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Alzheimer Disease with a site in Italy, or all of them as a file.
02

Study summary

The variable course of Alzheimer's disease (AD) and the paucity of adequate cures urges to implement new strategies for its early detection and clinical intervention. Studying the etiopathogenesis and pathophysiological mechanisms of AD is a necessary prerequisite for the development of new biomarkers and innovative therapies. Contrarily to anatomical structures, cortical connectivity networks are already deteriorated in early AD and could be a reliable marker of early cognitive decline. Our aim is to characterize the neurophysiological parameters in mild AD, in patients with mild cognitive impairment and in matched healthy subjects to identify discriminating criteria. Concurrently, the study of AD onset and progression in a mouse model, will allow evaluating the causal effect of inflammation on disease progression and to develop a new class of biomimetic anti-inflammatory nanoparticles formulated to have the intrinsic ability to induce brain's activated microglia to an M2 phenotype.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • EEG
  • functional connectivity
  • neuroinflammation
  • nanoparticles
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

100 AD and 100 MCI individuals from the dementia clinical centres of North Sardinia and local sections of patients¿ associations and 100 HC will be recruited for the study. To investigate past/present health status and medications, baseline medical screening will be performed by general clinical and anthropometric examinations

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • mild AD and patients with mild cognitive impairment (MCI).

Exclusion criteria

Exclusion Criteria:

  • major psychosis, genetic, metabolic and other neurological disorders, acute or chronic non-compensated medical illness
  • any medical or drug-related condition affecting cognitive or mood status
  • history or current alcohol/illicit drug abuse.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
300 participants (actual)
Patient registry
No

Groups and cohorts

  • AD
  • MCI
  • HC
06

What researchers measure

Primary outcomes

  1. Identification of Disease-Associated Phenotypes in MCI and AD

    Time frame: through study completion, an average of 1 year

  2. Identification of Disease-Associated Early Interventions in MCI and AD

    Time frame: through study completion, an average of 1 year

  3. Predictive Power of EEG-Based Brain Network Analyses for MCI to AD Conversion

    EEG power spectral density

    Time frame: through study completion, an average of 1 year

  4. Evaluation of Targeting Efficiency of Activated vs Native Leukosomes in Brain Inflammation

    Time frame: through study completion, an average of 1 year

  5. Evaluation Trafficking Kinetics of Activated vs Native Leukosomes in Brain Inflammation

    Time frame: through study completion, an average of 1 year

  6. Assessment of Activated Leukosomes in Inducing Anti-Inflammatory Polarization of Macrophages

    Time frame: through study completion, an average of 1 year

  7. Assessment of Activated Leukosomes in Glial Cells

    Time frame: through study completion, an average of 1 year

07

Study locations

2 sites
  • IRCCS San Raffaele
    Roma, Italy 00163, Italy
  • Azienda Ospedaliero-Universitaria di Sassari
    Sassari, Sassari 07100, Italy
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Dec 2025, 31 months.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's 31 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

Primary completion moved once since we started tracking on Sep 25, 2026: May 2025 → Dec 2025, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Mar 3, 2025
StartActual
May 18, 2023
Primary completionActual
Dec 31, 2025was May 2025
CompletionActual
Dec 31, 2025
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 4, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Italy)
  • IRCCS San Raffaele · Roma, Italy
  • Azienda Ospedaliero-Universitaria di Sassari · Sassari, Italy
Show 2 removed
  • IRCCS San Raffaele · Roma, Italy
  • Azienda Ospedaliero-Universitaria di Sassari · Sassari, Italy
Nov 4, 2026
Primary completion
May 17, 2025→Dec 31, 2025 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Completed
    2 sites added, 2 sites removed
    Show 2 added (2 Italy)
    • IRCCS San Raffaele · Roma, Italy
    • Azienda Ospedaliero-Universitaria di Sassari · Sassari, Italy
    Show 2 removed
    • IRCCS San Raffaele · Roma, Italy
    • Azienda Ospedaliero-Universitaria di Sassari · Sassari, Italy
    Primary completion May 17, 2025→Dec 31, 2025 (now actual)
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06855368
Lead sponsor
IRCCS San Raffaele Roma
Responsible party
Sponsor
First posted
Mar 3, 2025
Start date
May 18, 2023
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
Nov 4, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion